NR3C2

Across TCGA pan-cancer cohorts, NR3C2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NR3C2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NR3C2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NR3C2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and COAD are the cancer types where NR3C2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NR3C2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.890	<.001	11	view →
LSCC	Male	II,III,IV	−0.724	<.001	7	view →
COAD	All	All	−0.878	.007	6	view →
PDAC	Male	All	−0.940	<.001	5	view →
LUAD	Female	All	−0.382	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NR3C2–CCRCC

Open the CCRCC breakdown →